The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of an antimicrobial agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and in inhibiting the spread into the bloodstream of pathogenic oral bacteria, associated bacterial toxins and endotoxins, and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compositions by topically applying to the oral cavity, a safe and effective amount of an antimicrobial agent to promote and/or enhance whole body health in humans and other animals.

A digestive system disease therapeutic or preventive agent containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: wherein X is a -CW<1>R<1> group, a -COCOR<2> group, a -CW<1>NHCOR<2> group, a -C(=W<1>)W<2>R<3> group or a -CW<1>N(R<4>)R<5> group; Y is an alkyl group, a -CW<3>R<6> group, a -COCOR<7> group, a -NHCOR<7> group, a -C(=W<3>)W<4>R<8> group, a -(NH)mSO2R<9> group, a -(NH)mSO2OR<10> group or a -(NH)mSO2N(R<11>)R<12> group; each of R<1>, R<6> and R<9> is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R<2> and R<7> is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R<3>, R<8> and R<10> is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R<4>, R<5>, R<11> and R<12> is an alkyl group; each of W<1>, W<2>, W<3> and W<4> is an oxygen atom or a sulfur atom; and m is 0 or 1.

The present invention describes a pharmaceutical, veterinary or alimentary composition comprising one or more bacterial strains capable of lowering the concentration of intestinal pathogenic peptides by means of peptidases of probiotic strains. The invention also relates to the use of such compositions, and a method for selection of probiotic strains. Also, the invention relates to novel bacterial strains.

The present invention relates to topical oral care compositions comprising in a pharmaceutically acceptable carrier a safe and effective amount of a host-response modulating agent including one or more of an anti-oxidant and modifier of cell redox status, anti-inflammatory agent, metalloproteinase inhibitor, vitamins and nutrients key to maintenance of a host response balance and inhibitor of activation of NF-kB in combination with one or a mixture of additional oral therapeutic actives selected from antimicrobial/antiplaque agents, biofilm inhibiting agents, antibiotics; analgesics and local anesthetic agents; dentinal desensitizing agents and odor masking agents. The present compositions are effective in treating and preventing bacteria-mediated diseases present in the oral cavity and in mediating host reaction to the presence of pathogenic bacteria in the oral cavity as well as the toxins and endotoxins, inflammatory cytokines and mediators released or prompted by these oral pathogens. By controlling bacteria-mediated diseases and conditions present in the oral cavity and modulating host reaction, spread into the bloodstream and other parts of the body of pathogenic bacteria and associated harmful substances is prevented or minimized.

The invention relates to compounds of formula (I), produced from the plant Garcinia punctata, chemical derivatives derived therefrom, a method for production and use thereof as medicaments, in particular, for the treatment and/or prophylaxis of bacterial infective diseases.

The present invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia and having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.

The present invention relates to a process for the preparation of a composition comprising unsaturated compounds, in particular polyunsaturated compounds, which comprises concentrating and purifying the compounds by contact with silicon and/or aluminum derivatives. The process of the invention represents an advantageous substitute of the usual distillation processes, coupled or not to chromatographic processes, and allows to isolate and remove polar byproducts.

The present invention relates to a visceral fat decreasing agent, a visceral fat accumulation inhibitor and a body fat distribution improver, each comprising as an active ingredient a thiazolidine derivative represented by the following formula (IV): wherein A<3> represents an optionally substituted phenyl or oxazolyl group.

The present invention relates to the use of calcium ion and/or sugars to minimize thermal aggregation of DNase and to the use of calcium ion to stabilize liquid solutions of DNase, the solutions having a pH of less than neutral. DNase is the active pharmaceutical principle and the solutions may contain other pharmaceutically acceptable excipients making them suitable for pharmaceutical administration. In the first instance, calcium ion/sugar minimizes the effects of thermal aggregation in the solution. In the second aspect, calcium ion stabilizes the lower pH solutions from protein precipitation.

The present invention provides soap, including glycerine and sapropel. It also provides therapeutic uses thereof.